DIRS.INFO The most relevant business & tech news

☆ GEHC gives reasons to look beyond temporary China woes and shares reverse higher
▼ + stars: | 2024-07-31 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

GE Healthcare on Wednesday morning reported a mixed second quarter and shares initially moved sharply lower. Organic revenue growth was 1%. We saw a continued acceleration of Vizamyl doses delivered in the U.S. in the second quarter. This is still a small contributor to sales growth but gives us optimism about its sales potential over the next few years." As a result, we're lowering our total company full-year organic revenue growth guidance."

Persons: Philips, It's, Eli Lilly, GEHC, —, Jay Saccaro, We're, Arduini, Peter Arduini, Jim Cramer's, Jim Cramer, Jim, Pavlo Gonchar Organizations: GE Healthcare, Management, Revenue, LSEG, General Electric, Philips, Siemens, Club, GE Healthcare YTD, GE Healthcare's, Care Solutions, Pharmaceutical Diagnostics, U.S, CNBC, Lightrocket, Getty Locations: China, Eisai, U.S

☆ Ozempic predecessor suggests potential for GLP-1 drugs in Alzheimer’s in early trial
▼ + stars: | 2024-07-30 | by ( Meg Tirrell | ) edition.cnn.com time to read: +7 min

“This is the first study that actually looked at a relatively large number of patients for whether there is any neuroprotective effect in Alzheimer’s disease,” Edison said. The trial enrolled predominantly people with mild Alzheimer’s disease, measured by a test known as the Mini-Mental State Examination, a scale that goes up to 30. The GLP-1 drug class also includes Eli Lilly’s Mounjaro and Zepbound, which use the active ingredient tirzepatide, which mimics not just the hormone GLP-1 but another called GIP. But it hasn’t announced any trials of its GLP-1 drugs in Alzheimer’s. GLP-1 drugs can have side effects, though, primarily gastrointestinal problems like nausea and vomiting.

Persons: liraglutide, “, ”, Maria Carrillo, Carrillo, Paul Edison, ” Edison, Edison, Eli Lilly’s Mounjaro, Alzheimer’s Lilly, hasn’t, Lilly, Lars Fruergaard Jorgensen, there’s, Dr, Sanjay Gupta, semaglutide Organizations: CNN, Alzheimer’s Association International Conference, Alzheimer’s Association, Novo Nordisk, Imperial College London, ”, Nordisk, ” Novo Nordisk, CNN Health, University of Oxford, Alzheimer’s Society, Alzheimer’s Locations: United Kingdom, Philadelphia, Alzheimer’s, ” Novo, Danish

☆ Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
▼ + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +5 min

George Frey | ReutersAn older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer's disease by protecting patients' brains, according to data from a mid-stage trial released on Tuesday. Novo Nordisk sells liraglutide as a diabetes and obesity drug under the brand names Victoza and Saxenda, respectively. Alzheimer's disease often causes the brain to shrink as the illness progresses because crucial nerve cells break down and stop working properly. By 2050, the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S. The ongoing EVOKE is examining semaglutide, the active ingredient in Wegovy and Ozempic, in nearly 2,000 Alzheimer's patients.

Persons: George Frey, Eli Lilly, liraglutide, Brian B, Bettencourt, Heather Snyder, Leqembi, Snyder, Dr, Paul Edison, Edison, Bobby Pugh, Bessie Pugh, Karen Pulfer Focht Organizations: Novo Nordisk Pharmaceutical, Reuters, Novo Nordisk, Imperial College London, Alzheimer's Association International Conference, Toronto Star, Getty, Alzheimer's Association, U.S, CNBC, Alzheimer's, Novo Nordisk's, Ave Locations: Provo , Utah, Danish, Philadelphia, Biogen, Novo, Bartlett , Tennessee, U.S

☆ Here are JPMorgan's top drug stock picks into earnings
▼ + stars: | 2024-07-29 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

JPMorgan is eyeing a few drug manufacturers ahead of their earnings reports as investors continue to sell out of major technology firms. This backdrop has analyst Chris Schott reviewing JPMorgan's top pharmaceutical and biotechnology stocks, which includes "stories that have clear upside potential to longer-term estimates" like Eli Lilly and Merck. Eli Lilly Pharmaceutical company Eli Lilly made the list. Schott said the firm is somewhat below consensus Wall Street estimates for Eli Lilly heading into second-quarter results on Aug. 8. LLY YTD mountain Eli Lilly stock.

Persons: Johnson, Merck —, Chris Schott, Eli Lilly, Merck, Schott, —, Regeneron Organizations: JPMorgan, Dow Jones, Johnson, Merck, US Major Pharma, Schott, FactSet, Pharmaceuticals Locations: Mounjaro, Novo

☆ Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Live Nation, 3M, Uber, Eli Lilly, Amazon, Coinbase & more
▼ + stars: | 2024-07-29 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Monday's biggest calls on Wall Street: Morgan Stanley reiterates Live Nation as overweight Morgan Stanley said shares of the entertainment concert company are compelling. " Cantor Fitzgerald reiterates Nvidia as overweight Cantor said the stock is still a top pick at the firm. Guggenheim upgrades Akamai to buy from neutral Guggenheim said shares of the cloud computing networking company have more room to run. Bank of America reiterates Apple as buy Bank of America said it's bullish heading into Apple earnings later this week. JPMorgan reiterates Eli Lilly as overweight JPM said the stock is a "core holding" ahead of earnings on August 8.

Persons: Morgan Stanley, Cantor Fitzgerald, Cantor, TD Cowen, AAPL, Wells, Booz Allen Hamilton, it's, Guggenheim, Piper Sandler, Charles Schwab, Piper, Schwab, Olin, Mizuho, Bill Brown's, Myers Squibb, JPMorgan, Eli Lilly, JPM, Evercore, Tesla, Oppenheimer, Raymond James, Davidson, Raymond James downgrades Organizations: NVDA, MU, Apple, Huawei, Booz, Guggenheim, RBC, Deutsche Bank, Northrop, Deutsche, JPMorgan, Uber, Holdings, 3M, " Bank of America, Bank of America, Edge, Barclays downgrades Bristol, Myers Squibb, Barclays, Bristol, Ford, Microsoft, Charter, HSBC Locations: China, underperform

☆ Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data
▼ + stars: | 2024-07-29 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. However, in an FT interview published earlier Monday, CEO Thomas Schinecker indicated that the firm's first obesity drug could come to market "significantly faster than people are expecting," potentially by 2028. Both CT-388 and CT-996 were acquired as part of Roche's purchase of U.S. biotech company Carmot Therapeutics, which completed in January. The promising results could see Roche emerge as a potential rival to obesity drug pioneers Novo Nordisk and Eli Lilly. Schinecker told CNBC last week that he expects the company to eventually offer a suite of obesity medications.

Persons: Roche, Nordisk's Wegovy, Eli Lilly, Thomas Schinecker, Teresa Graham, Roche's, Schinecker Organizations: Nordisk's, CNBC, Roche Pharmaceuticals, Carmot Therapeutics, Novo Nordisk Locations: U.S

☆ These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatments
▼ + stars: | 2024-07-28 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +6 min

With billions at stake, that's pretty much been a guarantee facing the current market leaders, Eli Lilly and Novo Nordisk , from the start. Their updates are likely to be joined by others in the coming months even as today's incumbents develop their own next-generation weight loss treatments. Other analysts have also grown more optimistic about the future of weight loss treatments. Orforglipron, a once-a-day oral GLP-1 drug that Lilly is working on, had shown a 3% weight loss at 4 weeks. The company is also exploring whether the weight loss treatment could be given only once a month.

Persons: Eli Lilly, drugmakers Roche, Lilly, Denmark's, Trung Huynh, Huynh, Rajesh Kumar, Kumar, Novo, Roche, Roche ADRs, Justin Zelin, Zelin, Viking's, HSBC's Kumar, Novo aren't, —, Nick Wells Organizations: Novo Nordisk, Viking Therapeutics, UBS, HSBC Global Research, Carmot Therapeutics, Food and Drug Administration, Viking, European Association for, Diabetes, Pfizer, Amgen, Therapeutics Locations: Swiss, Novo, San Antonio, Spain

☆ Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says
▼ + stars: | 2024-07-26 | by ( Weizhen Tan | ) www.cnbc.com time to read: +3 min

Weight loss drugs have drawn investor interest and shaken up other sectors in the past year or so. Novo Nordisk and Eli Lilly were two early winners of this trend, as their drugs dominate the weight loss drug market. Yuri Khodjamirian, fund manager at Tema ETFs, said both companies are a "very powerful duopoly." They're a lot more risky than the bigger ones who already have drugs on the market," Khodjamirian said. Tema ETFs offers actively managed exchange-traded funds, with a focus on health care and life sciences.

Persons: Eli Lilly, Yuri Khodjamirian, Goldman Sachs, Khodjamirian, Roche Organizations: Novo Nordisk, Tema, CNBC, Zealand Pharma, Viking Therapeutics, Tema Oncology, Mental Health Locations: Tema

☆ 10 things to watch in the stock market Friday after a tumultuous week
▼ + stars: | 2024-07-26 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

The data didn't sway the market odds on the Fed cutting interest rates three times this year, starting in September. The industrial conglomerate raised its full-year outlook. Two of the Club's industrial names, Honeywell and Dover , reported earnings this week with mixed fortunes for their stocks. Dexcom shares plunged more than 35% after the medical device company missed on revenue and cut its full-year outlook. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Bristol Myers, Abbott, Skechers, Lockheed Martin, L3Harris, Japan's Eisai, Eli Lilly, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Federal, Transportation, Electronics, Honeywell, Colgate, Palmolive, Abbott Laboratories, Libre, Deutsche Bank, Lockheed, EU, Novo Nordisk, Jim Cramer's Charitable, CNBC Locations: Dover

☆ European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
▼ + stars: | 2024-07-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

European drug regulators on Friday rejected the Alzheimer's treatment Leqembi from Biogen and Eisai , creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. But it almost always follows the drug regulator's recommendations. The European Medicines Agency's human medicines committee recommended against granting marketing authorization for Leqembi. Leqembi and Kisunla are milestones in the treatment of Alzheimer's after three decades of failed efforts to develop medicines that can fight the fatal disease. In 2021, the European Medicines Agency rejected Aduhelm.

Persons: Eisai, Leqembi, Eli Lilly, Kisunla, Aduhelm Organizations: U.S, European Commission, U.S . Food, Drug Administration, Medicines, European Medicines Agency, Alzheimer's Locations: Biogen, U.S, Japan, South Korea, China, Israel, Europe, Alzheimer's Europe

☆ Viking Therapeutics stock jumps 30% after drugmaker moves weight loss injection to late-stage trial
▼ + stars: | 2024-07-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Shares of Viking Therapeutics jumped more than 30% on Thursday after the biotech company a day earlier announced plans to advance its experimental weight loss injection into a late-stage trial earlier than expected. Viking is one of several small and large drugmakers hoping to compete in the space against Novo Nordisk and Eli Lilly , whose weight loss and diabetes GLP-1s have skyrocketed in demand over the last two years. During the call, Lian added that Viking expects to test VK2735 as a monthly injection in a future study. Viking Therapeutics' drug promotes weight loss by targeting a GLP-1 and another hormone called GIP. That pill caused 3.3% weight loss when compared to a placebo in an early-stage trial.

Persons: Eli Lilly, Viking, Brian Lian, Lian, Justin Zelin, Zelin, Eli Lilly's Zepbound Organizations: Viking Therapeutics, San, Novo Nordisk, Food and Drug Administration, FDA, Novo Nordisk's Wegovy Locations: San Diego

☆ Wegovy rival to be part of a suite of weight loss drugs, Roche CEO says following positive trial results
▼ + stars: | 2024-07-25 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

Roche said Thursday that its Wegovy rival weight loss drugs will be part of a suite of medicines aimed at combatting the effects of obesity. CEO Thomas Schinecker welcomed positive early stage trial results from the firm's two weight loss drug candidates as showing "best in disease potential." "We do believe we have two next generation GLP-1/GIPs that have a best in disease potential," he said of the obesity drugs. GLP-1s, or glucagon-like peptide 1 agonists, are a group of drugs used to treat diabetes and obesity. They form the basis of weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Persons: Roche, Thomas Schinecker, Schinecker, CNBC's, Nordisk's Wegovy, Eli Lilly's Zepbound Organizations: Nordisk's

☆ The 7 most renter-friendly big cities in the US
▼ + stars: | 2024-07-25 | by ( Madison Hoff | ) www.businessinsider.com time to read: +1 min

Raleigh, North Carolina, was the most renter-friendly among 98 cities analyzed by ApartmentAdvisor. AdvertisementAmid peak rental season, some cities are better suited than others for renters thinking about their next move. Raleigh, North Carolina, took the top spot on ApartmentAdvisor's list of the "The Most Renter-Friendly U.S. Cities in 2024." "We pretty much knew from other studies we've done that rent prices alone wouldn't be the only factor that would make a city renter-friendly," Lilly Milman, editor at ApartmentAdvisor, told Business Insider. This story is available exclusively to Business Insider subscribers.

Persons: ApartmentAdvisor, —, Lilly Milman Organizations: Service, Friendly U.S, Cities, Business Locations: Raleigh, North Carolina, Cedar Rapids , Iowa, Raleigh , North Carolina

☆ 2024 Paris Olympics viewer’s guide: NBC’s plans, Snoop Dogg, and the big ratings question
▼ + stars: | 2024-07-24 | by ( Richard Deitsch | ) www.nytimes.com time to read: +18 min

Follow our Olympics coverage in the lead-up to the Paris Games. The Paris Games will have more programming hours on the NBC broadcast network than any previous Olympics. NBC is upping its celebrity presence for its Olympic coverage in Paris, headlined by Snoop Dogg. “Research shows that it is a challenge to keep viewers after 10 p.m. ET,” NBC Olympics producer Rob Hyland said. NBCUniversal owns the U.S. media rights to the Olympic Games through 2032, so Paris (2024), Milan-Cortina (2026), Los Angeles (2028) and Brisbane (2032).

Persons: Peacock, Molly Solomon, NBC’s, “, ” Solomon, Solomon, Snoop, Snoop Dogg, Christian Petersen, Kelly Clarkson, Peyton Manning, Mike Tirico, Alex Cooper, Leslie Jones, Kevin Hart, Kenan Thompson, Colin Jost, Cooper, Simone Biles, Manning, Ryan Crouser, Jones, Katie Ledecky, Sha’Carri Richardson, Lily Collins, Anna Hall, Ledecky, LeBron James, Sydney McLaughlin, Kelly Campbell, Peacock’s, Scott Hanson, Andrew Siciliano, Jac Collinsworth, Matt Iseman, Akbar Gbajabiamila, ”, Al Michaels, Mark Lazarus, Sanya Richards, Ross, Rowdy Gaines, Tim Daggett, Laurie Hernandez, Samantha Peszek, Misty, Julie Foudy, Dwyane Wade, LaChina Robinson, Michael Phelps, Dan Hicks, Gaines, Maddie Meyer, they’ll, Rob Hyland, Andres Cantor, Rebecca Lowe, Craig Melvin, Ahmed Fareed, Damon Hack, Maria Taylor, Cara Banks, Laura Britt, Trenni Casey, Lindsay Czarniak, Carolyn Manno, Kathryn Tappen, John Roethlisberger, “ John, He’s, …, breaststroker Lilly King wagged, Ryan Murphy, Sunny Choi, Victor Montalvo, Joe Gesue, Ron Vaccaro, NBCU, it’s, NBCUniversal, Rick Cordella, Dan Goldfarb, Stuart Franklin Organizations: Paris, NBC, Paris Games, U.S, Tokyo Olympics, Olympics, NBC Olympics, NBC’s, Getty, NBC Sports, Tokyo Games, Beijing, Games, USA, CNBC, Golf Channel, Telemundo, Universo, NBCOlympics.com, “, ”, NFL, NBCUniversal Media, Paris La Défense, Research, Olympic, Grand Palais, Concorde, NBC Sports ’, Olympic Games, Cortina Locations: Paris, Beijing, Pyeongchang, South Korea, Central, Pacific, U.S, Paris ”, Teahupo’o, Tahiti, Rio de Janeiro, Brazil, China, Rio, Tokyo, Peacock, United States, Versailles, Grand, London, Russian, Norway, South Carolina, Milan, Los Angeles, Brisbane, French

☆ Why aren't there breakout YouTube stars like there used to be? A chat with 2 YouTube execs
▼ + stars: | 2024-07-23 | by ( Amanda Perelli | ) www.businessinsider.com time to read: +5 min

Read previewIf you consider yourself very online, you'd likely be able to name the early wave of top YouTube creators, from Lilly Singh and PewDiePie to Zoella and Tyler Oakley. AdvertisementDuring the early days of YouTube, there were only a handful of channels to watch with creators consistently making quality content. But now, the number of YouTube creators uploading content and making money from the platform has grown tremendously. Still, Allocca said he's noticed there are more successful creators than there used to be but fewer huge stars. AdvertisementSo, while there may be more opportunities for YouTube creators now, it may be a while before we see another rising star who can amass the broad appeal of someone like MrBeast.

Persons: —, Lilly Singh, PewDiePie, Tyler Oakley, it's, YouTube execs Amjad Hanif, Kevin Allocca, Hanif, Anthony Baroud, Aphmau, Krew, Alpha, Allocca, he's, There's, Gen, Ally Sheehan, Taylor Swift Organizations: Service, YouTube, Business, Brands Locations: Zoella, VidCon, Anaheim , California, North Carolina

☆ Alphabet moves past early stumbles in AI to deliver positive story to investors
▼ + stars: | 2024-07-23 | by ( Zev Fima | ) www.cnbc.com time to read: +12 min

Strong numbers in the company's search and cloud businesses more than offset the slight misses in the YouTube and network units. Cloud recorded a couple of big firsts: exceeding $10 billion in revenue, along with $1 billion in operating income. Whereas investors were — and many still are — concerned about what generative AI might mean for Alphabet's search revenue, the opposite appears to be the case, at least for now. Google Cloud revenue grew roughly 28% to more than $10 billion for the first time. Strong numbers in the company's search and cloud businesses more than offset the slight misses in the YouTube and network units.

Persons: we're, capex, Sundar Pichai, Pichai, Philipp Schindler, Schindler, Ruth Porat, Eli Lilly, Anat Ashkenazi, Jim Cramer's, Jim Cramer, Jim, Loren Elliott Organizations: YouTube, Microsoft, Club, Nvidia, Lens, CTV, Nielsen, Google, buybacks, CNBC, Government, Society, Calif, Bloomberg, Getty, Meta Locations: That's, U.S, Stanford

☆ Swimming at the 2024 Paris Olympics: U.S. hopes, schedule and how to watch
▼ + stars: | 2024-07-22 | by ( Zack Pierce | ) www.nytimes.com time to read: +8 min

ET) W 100m fly W 100m fly semis (2:30 p.m.) W 400m free M 400m free (2:42 p.m.) M 100m breast W 400m free (2:52 p.m.) M 400m free M 100m breast semis (3:12 p.m.) W 4x100m free W 4x100m free (3:34 p.m.) M 4x100m free M 4x100m free (3:44 p.m.) July 28 Heats Semis/finals (approx. ET) M 200m free M 400 IM (2:30 p.m.) M 400m IM W 100m fly (2:40 p.m.) W 100m breast M 200m free semis (2:46 p.m.) M 100m back W 100m breast semis (3:10 p.m.) W 200m free M 100m back semis (3:32 p.m.) M 100m breast (3:44 p.m.) W 200m free semis (3:50 p.m.) July 29 Heats Semis/finals (approx. ET) M 200m fly M 100m free semis (2:30 p.m.) M 100m free M 200m fly semis (2:42 p.m.) W 1,500m free W 100m back (2:56 p.m.) W 100m free M 800m free (3:02 p.m.) M 200m breast W 100m free semis (3:25 p.m.) M 4x200m free M 200m breast semis (3:47 p.m.) M 4x200m free (4:01 p.m.) July 31 Heats Semis/finals (approx. ET) W 200m breast W 100m free (2:30 p.m.) M 200m back M 200m fly (2:36 p.m.) W 200m fly W 200m fly semis (2:43 p.m.) W 1,500m free (3:07 p.m.) M 200m back semis (3:37 p.m.) W 200m breast semis (3:51 p.m.) M 200m breast (4:15 p.m.) M 100m free (4:22 p.m.) Aug. 1 Heats Semis/finals (approx. ET) M 100m fly M 50m free (2:30 p.m.) W 200m IM W 200m back (2:30 p.m.) W 800m free M 200m IM (2:43 p.m.) Mixed 4x100m medley M 100m fly semis (3 p.m.) W 200m IM semis (3:22 p.m.) Aug. 3 Heats Semis/finals (approx.

Persons: Katie Ledecky, Caeleb Dressel, Dressel, Regan Smith, Gretchen Walsh, Kate Douglass, Lilly King, Simone Manuel, Torri Huske, Alex Walsh, Katie Grimes, Grimes, Bobby Finke, Chase, Ryan Murphy, Kieran Smith, Thomas Heilman, Chris Guiliano, There’s, Ariarne, Summer McIntosh, Ledecky, McIntosh, Titmus, Erika Fairweather, Fairweather, swimming’s, Maddie Meyer Organizations: U.S ., Olympic, Paris La Défense, NBC, Telemundo, Universo, USA, U.S, Ledecky, Notre Dame, didn’t, June’s U.S Locations: Paris, Tokyo, USA, Chase Kalisz, East Germany, Ledecky

☆ 10 things to watch in the stock market Friday, including tech rotation and Eli Lilly approval
▼ + stars: | 2024-07-19 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

10 things to watch Friday, July 19 Can tech stocks and the overall market stabilize to end the week? That's what to watch after a brutal week for the "Magnificent Seven," which fell victim to a rotation away from 2024 winners. PPG Industries lowered its organic sales growth outlook, putting pressure on the stock. The credit card giant, known for its affluent customer base, also lifted its 2024 earnings outlook. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: CrowdStrike, Piper Sandler, Halliburton, SLB, Eli Lilly, Morgan Stanley, Bill Newlands, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Palo Alto Networks, Netflix, JPMorgan, PPG Industries, American Express, Novo Nordisk, Arm Holdings, Barclays, Molson Coors, Constellation Brands, Modelo, Corona, Jim Cramer's Charitable, CNBC Locations: Palo, China

☆ Which Weight Loss Drug Should You Choose (if You Get to Choose)?
▼ + stars: | 2024-07-19 | by ( Gina Kolata | ) www.nytimes.com time to read: +1 min

People with obesity now have a choice between two powerful drugs to help them lose weight. One is semaglutide, sold by Novo Nordisk as Wegovy for obesity treatment and as Ozempic for diabetes. A recent study suggested that people lost more weight taking Mounjaro than they did taking Ozempic, and it may leave you wondering: Which should I take? Is one weight loss drug really better than the other? All of the information available comes from “highly flawed studies,” said Dr. Diana Thiara, medical director of the weight loss clinic at the University of California, San Francisco.

Persons: Eli Lilly, I’m, ”, Diana Thiara Organizations: Novo Nordisk, University of California Locations: San Francisco

☆ How CrowdStrike's stumble could impact our cybersecurity stock Palo Alto
▼ + stars: | 2024-07-19 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Shares of Club holding Palo Alto Networks rose more than 1% Friday after an update from its cybersecurity rival CrowdStrike caused a widespread IT outage across the globe. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, CrowdStrike, Nikesh Arora, Jeff Marks, Jeff, Eli Lilly, Jim, Lilly, Roche, Eli Lilly's, Jim Cramer's Organizations: CNBC, Nasdaq, Dow Jones, Palo Alto Networks, Palo Alto, Novo Nordisk Locations: Danish

☆ Novo Nordisk, Eli Lilly have strong first-mover advantage in weight loss drug market, analyst says
▼ + stars: | 2024-07-18 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovo Nordisk, Eli Lilly have strong first-mover advantage in weight loss drug market, analyst saysEmily Field, head of European pharmaceuticals research at Barclays, says it's too early to say what the competitive landscape will look like in five years for the weight loss drug market, as many trials are still in an early stage.

Persons: Eli Lilly, Emily Field, it's Organizations: Novo Nordisk, Barclays

☆ Jim Cramer supports megacaps for the long term, even as Wall Street continues to sell
▼ + stars: | 2024-07-18 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

As megacaps continue to decline, CNBC's Jim Cramer said he remains optimistic about their prospects in the long run. "You just need to get over the hump, a hump that periodically scares people out of this whole asset class." Cramer said he always encourages investors take profits on winners when they can, otherwise it's possible to "get obliterated." And owning losers can feel more difficult than owning winners because it's more obvious why the latter might be on the decline, he added. Cramer said the arguments against these stocks are "for real," but similar to what has been said about them for years.

Persons: megacaps, CNBC's Jim Cramer, Cramer, Eli Lilly Organizations: Meta, Microsoft, Nvidia, Tesla

☆ We're upgrading Eli Lilly after an overdone sell-off on competition fears
▼ + stars: | 2024-07-18 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Upgrading Lilly: Shares of Eli Lilly have been hit hard since making a new closing high on Monday. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Eli Lilly, Roche, there's, Lilly, we'll, Jim Cramer's, Jim Organizations: CNBC, Nasdaq, Energy, Nvidia, Lilly, Novo Nordisk, Netflix, PPG Industries, American, Halliburton, Jim Cramer's Charitable Locations: Swiss

Here's a rapid-fire update on all 34 stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. Costco : While Costco gets nearly 7% of its sales from China, Jim said it's unlikely its business would be threatened by geopolitics given the company's popularity in the country. Constellation Brands : There's no doubt that the Modelo and Corona parent is a less attractive stock under Trump compared with Biden. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jim Cramer's, Jim, Donald Trump, Abbott's, Reckitt Benckiser, we're, there's, it's, Biden, Dupont, Trump, Walt Disney, Nelson Peltz, Jim said, Estee Lauder, Eaton, Honeywell's, Washington that's, Eli Lilly, Roche, Eli Lilly's, Lilly, Sen, J.D, Vance of, Morgan Stanley, ChatGPT, chipmaker, Laxman Narasimhan, Stanley Black, Decker, rightsizing, Wells, Wynn, he's, Jim Cramer, Brendan McDermid Organizations: Jim Cramer's Charitable Trust, CNBC, Trump, Abbott Laboratories, AMD, Broadcom, VMWare, Costco, Coterra Energy, White, Bloomberg, Federal, Motors, Ford, GE Healthcare, Big Tech, Honeywell, Air Products, Linde, Meta, Microsoft, Investors, OpenAI, Republican, Palo Alto Networks, Palo, Procter & Gamble, Biden, Constellation Brands, Modelo, The, TJX, Wynn Resorts, Club, Jim Cramer's Charitable, Traders, New York Stock Exchange Locations: China, Dover, U.S, Washington, Vance of Ohio, Meta, Taiwan, Israel, Gaza, Corona, Wells Fargo, Macau, New York City

☆ CNBC Pro Talks: From weight loss drugs to AI winners, CIO set to reveal his top stocks
▼ + stars: | 2024-07-16 | by ( ) www.cnbc.com time to read: +2 min

Weight loss drugs and artificial intelligence have been dominating headlines, with investors betting that stocks in both categories have big potential upside. On Wednesday's Pro Talks , CNBC's Senior Technology Correspondent Arjun Kharpal will ask Tema ETFs' Yuri Khodjamirian how to best invest in these areas and more. Tema ETFs offers actively managed ETFs, with a focus on healthcare and life sciences. Before Tema ETFs, Khodjamirian spent over a decade at Majedie Asset Management, overseeing U.K. and global portfolios. Click here to join CNBC Pro Talks on Wednesday, July 17, at 7 a.m.

Persons: Arjun Kharpal, Yuri Khodjamirian, Eli Lilly, he'll, Khodjamirian Organizations: Tema, Novo Nordisk, pharma, Majedie Asset Management, Income, CNBC, Nvidia, Scotiabank Locations: Tema, —, U.S, U.K, India

Search resuls for: "lilly"

25 mentions found